Celmatix Inc. With a mission to change the future of medicine, Celmatix aims to address the challenges faced by one in three women who experience conditions caused by poor ovarian health. Unlike traditional treatments introduced over 50 years ago, Celmatix focuses on decoding ovarian function, which plays a critical role in overall endocrine function.

Celmatix has amassed the largest structured dataset on ovarian health and outcomes globally, driving their industry-leading discovery program. This program includes proprietary cohorts, annotations, and research tools, covering a wide range of reproductive and genomic data. In addition, Celmatix has established strategic partnerships with industry leaders to develop innovative women's health therapeutics, including Evotec and Bayer.

Furthermore, Celmatix is actively involved in researching and developing next-generation female contraceptive drug discovery, with support from the Bill & Melinda Gates Foundation. Their breakthroughs in drug programs, such as the world's first oral FSH receptor agonist drug and novel PCOS drug program, have garnered significant attention and recognition. With a strong commitment to advancing women's health, Celmatix is revolutionizing the field and paving the way for better treatments and interventions.

Contact them today to learn more about their groundbreaking initiatives and the future of ovarian health